Press Releases

Novartis announced that the US Food and Drug Administration (FDA) has approved the following expanded indication for Entresto® (sacubitril/valsartan): to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with chronic heart failure.1 Benefits are most clearly evident in patients with left ventricular ejection fraction (LVEF) below normal.1 The label also states LVEF is a variable measure and clinical judgment should be used in deciding whom to

Cend Therapeutics, Inc., a clinical-stage biotech company, and Qilu Pharmaceutical, a major Chinese pharmaceutical company, announced that the companies have entered a Collaboration and License Agreement to develop and commercialize Cend’s investigational drug, CEND-1, in Greater China. Cend presented favorable clinical results at the European Society for Molecular Oncology (ESMO) meeting September 2020 and is advancing into Phase 2 clinical trials in pancreatic cancer with CE

Cytovia Therapeutics, Inc., a biopharmaceutical company developing allogeneic “off-the-shelf” gene-edited Natural Killer (NK) and Chimeric Antigen Receptor (CAR)-NK cells derived from induced pluripotent stem cells (iPSCs), and Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS) a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), announced today that they have entered into a strategic research and deve

Onward Therapeutics SA (Onward) announced today the execution of a worldwide exclusive license and co-development agreement with Biomunex Pharmaceuticals SAS (Biomunex), Paris, France, of a bispecific antibody targeting two immune checkpoints. Biomunex grants the rights for Onward to pursue development, manufacture and commercialization of this first-in-class bispecific antibody. Onward and Biomunex will jointly develop the antibody during the preclinical and early clinical program.

Lysogene, a phase 3 biopharmaceutical company relying on a gene therapy technological platform targeting central nervous system (CNS) diseases, today announces that the US regulatory agency (FDA ) approved its Investigational New Drug (IND) application for LYS-GM101, its gene therapy drug candidate for the treatment of GM1 gangliosidosis, a serious and life-threatening pediatric disease. LYS-GM101 builds on Lysogene's extensive experience in the clinical development of gene therapies base

MedPharm Ltd, the world’s leading contract service provider of contract topical and transdermal product design and formulation development services, has launched its Scientific Advisory Committee, headed by company founder and Board member, Professor Marc Brown. Marc Brown has served as MedPharm’s Chief Scientific Officer for over 20 years and will be stepping down from his CSO role to chair the newly formed committee. Comprised of world-renowned international experts, t

Jasper Therapeutics, Inc., a biotechnology company focused on hematopoietic cell transplant therapies, announced the launch of a Phase 1/2 clinical trial to evaluate JSP191, Jasper’s first-in-class anti-CD117 monoclonal antibody, as a targeted, non-toxic conditioning regimen prior to allogeneic transplant for sickle cell disease (SCD). Jasper Therapeutics and the National Heart, Lung, and Blood Institute (NHLBI) have entered into a clinical trial agreement in which NHLBI will serve as t

Ensoma, a company that formally launched with the mission of expanding the curative power of genomic medicine by pioneering a next-generation in vivo approach, announced it has entered into a strategic collaboration with Takeda Pharmaceutical Company Limited (“Takeda”). The agreement grants Takeda an exclusive worldwide license to Ensoma’s Engenious™ vectors for up to five rare disease indications. Takeda will make an equity investment of $10 million in Ensoma’s

Seagen Inc. and Genmab A/S announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking accelerated approval for tisotumab vedotin. This BLA requests FDA approval of tisotumab vedotin for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy. The submission is based on the results of the innovaTV 204 pivotal phase 2 single-arm clinical trial evaluating tisotumab vedot

Psyence Group Inc., through its wholly-owned subsidiary Psyence Therapeutics Corp. (“Psyence”), is pleased to announce it has entered into a Research Collaboration Agreement with MycoMeditations Inc (“MycoMeditations”), a leading psilocybin retreat provider to conduct an observational study of the efficacy of naturally derived psilocybin. The Psyence Group is a leading platform in naturally derived psychedelic therapy and the development and commercialization of relate